ARTL — ARTELO BIOSCIENCES, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1621221 ·
Last close
$1.68
Market Cap
$1.57M
52W High
$179.19
52W Low
$1.62
ADV30
36,771
Next earnings
—
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,505,000 -2,427,000 6,459,000 4,198,000 1,462,000
Mar 2026 0 — -2,689,000 -2,958,000 12,518,000 10,273,000 5,846,000
Dec 2025 0 — -2,786,000 -4,166,000 2,801,000 600,000 4,073,000
Sep 2025 0 — -3,089,000 -3,120,000 4,267,000 1,720,000 4,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,633,000
Investing CF
$-62,000
Financing CF
$14,847,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-33.66
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-68,400,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,336,000
Pretax Income TTM
$-12,671,000
Interest Exp TTM
$335,000
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -11,404,000 -12,879,000 2,801,000 4,073,000 -1,272,000 -8,520,000
Dec 2024 0 -10,108,000 -9,826,000 4,698,000 1,841,000 2,857,000 -8,350,000
Dec 2023 0 -9,930,000 -9,289,000 13,043,000 1,291,000 11,752,000 -8,207,000
Dec 2022 0 -10,287,000 -10,083,000 20,424,000 1,021,000 19,403,000 -8,008,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-12,671,000
OpCashFlow TTM
—
Assets (Latest)
$6,459,000
Forward EPS
$-0.88

Peers — same industry

TickerNameMarket CapLastDaily %
EMMA Emmaus Life Sciences, Inc. $1.61M $0.02 —
LIFD LFTD PARTNERS INC. $1.63M $0.11 —
RNAZ Transcode Therapeutics, Inc. $1.49M $1.41 —
HCWB HCW Biologics Inc. $1.43M $0.78 —
CPMD CANNAPHARMARX, INC. $1.42M $0.00 —

News headlines (Yahoo Finance, 1h cache)

Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
2026-11-12 13:00 · Yahoo
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
2026-10-29 13:00 · Yahoo
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
2026-10-26 11:55 · Yahoo
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
2026-10-07 12:48 · Yahoo
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
2026-09-23 11:33 · Yahoo
Artelo Biosciences Announces Reverse Stock Split
2026-08-27 12:00 · Yahoo
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
2026-08-17 12:52 · Yahoo
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
2026-08-13 12:00 · Yahoo
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
2026-07-22 12:39 · Yahoo
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
2026-07-16 12:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.